NDAORALTABLET
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
INPEFA (sotagliflozin) by Lexicon Pharmaceuticals is sodium-glucose transporter 2 inhibitors [moa]. Approved for type 2 diabetes mellitus, heart failure. First approved in 2023.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INPEFA (sotagliflozin) is an oral SGLT2 inhibitor approved in May 2023 for type 2 diabetes, heart failure, type 1 diabetes, chronic kidney disease, and diabetic nephropathy. It works by inhibiting sodium-glucose cotransporter 2 in the kidneys, promoting urinary glucose excretion and reducing cardiovascular and renal workload. The drug targets patients with multiple comorbidities requiring cardio-renal protection.
$0.659MPart D
GrowthStable
4.4 years to LOEEarly-stage commercial asset with 4.5 years of patent protection; team building and market development phase underway.
Mechanism of Action
Sodium-Glucose Transporter 2 Inhibitors
Pharmacologic Class:
Sodium-Glucose Cotransporter 2 Inhibitor
Indications (2)
Worked on INPEFA at Lexicon Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.